Compares two ways of giving interferon with antiviral pills for chronic hepatitis B

Trial details

Who runs it

Anhui Medical University

Trial code

NCT05922306

Record updated

28 June 2023

Original description

Previous studies have shown that there are alterations in the number and affinity of interferon receptors during interferon therapy and that such alterations recover to varying degrees some time after the end of treatment. It can be conjectured that the rest period of pulsed therapy facilitates the recovery of type I interferon receptors and thus the next round of IFN therapy compared to a continuous regimen of interferon.Read full original descriptionShow less

A Multicenter, Prospective Cohort Study: Efficacy of NA Combined With PEG-IFN-α2b Continuous Versus Pulsed Therapy for 96 Weeks in Patients With Chronic Hepatitis B.

Previous studies have shown that there are alterations in the number and affinity of interferon receptors during interferon therapy and that such alterations recover to varying degrees some time after the end of treatment. It can be conjectured that the rest period of pulsed therapy facilitates the recovery of type I interferon receptors and thus the next round of IFN therapy compared to a continuous regimen of interferon.

Inclusion: Age 18 to 60 years, both sexes (both 18 and 60 years); HBsAg positive for more than 6 months; NAs treated patients on continuous NA therapy for more than 6 months with HBsAg ≥ 1500 IU/ml and HBV-DNA < 500 IU/ml at enrolment; Primary treated patients with surface antigen >1500 IU, unlimited E antigen and unlimited HBV DNA at enrolment, meeting the treatment indications of the 2019 edition of the guidelines for the prevention and treatment of chronic hepatitis B; negative urine or serum pregnancy test within 24 hours prior to the first dose (for women of childbearing age).

Exclusion: methaemoglobin greater than 100ng/ml at screening; or methaemoglobin that has not remained stable for 3 months prior to the trial and/or liver imaging suggestive of liver tumours; History of severe epilepsy or current treatment with anti-epileptic drugs. Unstable control of diabetes mellitus, hypertension, thyroid disease, etc. Patients with a history of severe retinopathy or as indicated by other evidence of retinopathy; Combined active hepatitis A, C, D, E and/or HIV infection; History of severe psychiatric illness, especially depression. Major psychosis defined as major depressive disorder or psychosis, suicide attempts, hospitalisation for psychosis or incapacity for a period of time due to psychosis; history of immune-mediated disease (e.g. inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune haemolytic anaemia, scleroderma, severe psoriasis, rheumatoid arthritis) or abnormally elevated levels of autoimmune antibodies; Patients with severe combined diseases of the heart, lungs, kidneys, brain, blood and other vital organs, combined with other malignancies; History of any organ transplantation and existing functional grafts (except corneal or hair transplants); Patients who are allergic to interferon and its drug components and who, in the judgment of the investigator, are unsuitable for interferon application; decompensated liver disease (Child-Pugh score ≥ 7), meaning that patients will be excluded if one of the following is met: prolonged prothrombin time ≥ 3 seconds, serum bilirubin > 34umol/L, history of hepatic encephalopathy, history of oesophageal variceal bleeding, ascites; Neutrophil count < 1.5 x 10\^9/L or platelet count < 90 x 10\^9/L and creatinine > 1.5 ULN; Patients who are on future and intend to continue to use tibivudine; pregnant or lactating women or patients with planned pregnancy during the study period and unwilling to use contraception; Patients who, in the opinion of the investigator, are not suitable for participation in this study.

ClinicalTrials.gov NCT05922306